



# Tumor Markers

AIA-PACK® SERIES

## Meet the Challenges of Oncology Testing



Tosoh is committed to delivering the highest standard of quality, precision and accuracy in clinical diagnostics to aid in the fight against cancer. Our extensive tumor marker menu offered in a unique dry reagent test cup technology combined with our automated immunoanalyzers provide a comprehensive solution for oncology testing.

### **Biotin-free immunoassay designs**

Minimizes the risk of false lab test results

### **90-day calibration stability**

Reduces cost, time and calibration frequency

### **Wide dynamic ranges**

Delivers high-sensitivity results for proper patient care

## TOSOH BIOSCIENCE

[www.tosohbioscience.us](http://www.tosohbioscience.us)

Correlation with gold standard methods



Automated workflows



Accurate & precise



Biotin-free immunoassays



Extensive test menu



Specific & sensitive



Choose Wisely.  
Choose Tosoh.



Up to 90 day calibration stability



10 minute incubation times

### Universal Reagent

Tosoh's AIA-PACK test cup format works with every Tosoh automated immunoassay system allowing for a seamless transition from one system to the other, ensuring consistent results in an efficient and economical process.

### Save Time and Money

Tosoh's AIA-PACK test cups are single, unitized cups that use a dry reagent format that ensures calibration stability of up to 90 days.

### No Contamination, More Traceability

Because there is no transfer of reagents the risk of contamination is eliminated. The unique bichromatic fluorescence kinetic measurement ensures a high analytical and functional sensitivity for all assays. AIA-PACK test cups and trays are labelled with the assay code and lot number for automated scheduling and inventory.

*Tosoh products are for Prescription Use Only as In-Vitro Diagnostics*



**Tosoh Bioscience, Inc.**  
3600 Gantz Rd  
Grove City, OH 43123  
Tel: (800) 248-6764  
Fax: (650) 615-0415  
www.tosohbioscience.us

## Tumor Markers Available

Total PSA

27.29

CA 125

CA 19-9

AFP

CEA



**AIA®-360**



**AIA-900 Benchtop**

AVAILABLE FOR LABS AND WORKLOADS OF ALL SIZES



**AIA-900 with 9 Tray Sorter**  
Also available with 19 tray sorter option and as Loader model



**AIA-2000**

### References

1. Prestigiacomo, et al. A Comparison of 4 Ultrasensitive Prostate Specific Antigen Assays for Early Detection of Residual Cancer after Radical Prostatectomy. The Journal of Urology 1994; 152: 1515-1519.
2. Andrew W. Roddam, et al. Assessing the Clinical Impact of Prostate-Specific Antigen Assay Variability and Nonequimolarity: A Simulation Study Based on the Population of the United Kingdom Clinical Chemistry. Vol. 50, Issue 6 June, 2004
3. Jean-Sébastien B., Thomas B., THE CLINICAL IMPACT OF WHO STANDARDIZATION OF PSA ASSAYS. JMB 27: 161-169, 2008
4. Klee, G., et al. MUC1 Gene-Derived Glycoprotein Assays for Monitoring Breast Cancer (CA15-3. CA 27.29, BR). Arch Pathol Lab Med -Vol 128, October 2004.